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Abstract
Background: Antidepressants have been shown to affect levels of brain-derived neurotrophic factor (BDNF) and
VGF (non-acronymic) whose transcriptions are dependent on cAMP response element binding protein (CREB) in
long term treatment. The aim of this study was to verify the subacute antidepressant effects of crocin, an active
constituent of saffron (Crocus sativus L.), and its effects on CREB, BDNF, and VGF proteins, transcript levels and
amount of active, phosphorylated CREB (P-CREB) protein in rat hippocampus.
Methods: Crocin (12.5, 25, and 50 mg/kg), imipramine (10 mg/kg; positive control) and saline (1 mL/kg; neutral
control) were administered intraperitoneally (IP) to male Wistar rats for 21 days. The antidepressant effects were
studied using the forced swimming test (FST) on day 21 after injection. Protein expression and transcript levels of
genes in the rat hippocampus were evaluated using western blot and quantitative reverse transcription-polymerase
chain reaction (qRT-PCR), respectively.
Results: Crocin significantly reduced the immobility time in the FST. Western blot analysis showed that 25 and
50 mg/kg of crocin increased the levels of CREB and BDNF significantly and dose dependently. All doses of crocin
increased the VGF levels in a dose-dependent manner. Levels of p-CREB increased significantly by 50 mg/kg dose
of crocin. Only 12.5 mg/kg crocin could significantly increase the transcript levels of BDNF. No changes in CREB
and VGF transcript levels were observed in all groups.
Conclusions: These results suggest that crocin has antidepressant-like action by increasing CREB, BDNF and VGF
levels in hippocampus.
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Background
Depression, a serious and prevalent mental disorder, has
been predicted to be one of 10 leading causes of disabil-
ities that affects up to 21% of world population by 2020
[1]. Due to side effects including inability to drive a car,
dry mouth, constipation, and sexual dysfunction, the
majority of patients have low compliance and refuse to
take synthetic antidepressants in appropriate doses [2,3].
Thus, there is a need for more tolerable and less toxic
agents such as natural plant products which are import-
ant sources of new antidepressant drugs [4,5]. Contrary
to what is expected, existing antidepressant drug treat-
ments which based on the monoamine hypothesis are
just effective in almost one-third of depressed patients.
Moreover, clinical manifestations take 3–4 weeks to
start; although changes in synaptic monoamine levels
occur within hours. This delay in clinical efficacy may be
due to neurobiological adaptive mechanisms in hippo-
campus including alterations in synaptic plasticity and
neurogenesis which require synthesis of new proteins
[6-10]. CREB (cAMP response element binding protein)
is a transcription factor upregulated and phosphorylated
by chronic antidepressant treatment. Phosphorylation
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promotes the association of CREB with CREB-binding
protein, a co-activator protein that plays role in assembly
of an active transcription complex, enabling target gene
expression [11]. VGF (non-acronymic) and BDNF (brain-
derived neurotrophic factor) whose transcriptions are
dependent on CREB, involved in depressive disorders.
VGF is a neuropeptide which enhances hippocampal
synaptic plasticity and has roles in energy balance and
regulation of homeostasis. It also acts as antidepressant-
like agent in the forced swimming test (FST) behavioral
model of depression [7]. BDNF, widely expressed in mam-
malian brain, has been implicated in survival of neurons
during hippocampal development, neural regeneration,
synaptic transmission, synaptic plasticity, and neuro-
genesis [12].
Crocus sativus L. (Iridaceae) stigma commonly known
as saffron is widely cultivated in Iran and is used in
modern and traditional medicines. In addition, results of
different studies on pharmacological properties of saf-
fron and its constituents, crocetin, crocin and safranal,
are similar to findings as described by Avicenna. Crocin
(crocetin digentiobiose ester), a unique water-soluble
carotenoid, is one of the pharmacological active constitu-
ent of saffron [13,14]. Extensive studies has evaluated saf-
fron extracts and crocin for their pharmacological benefits
such as anti-tumor and cytotoxic [15-19], antioxidant
[20], antinociceptive and anti-inflammatory [21,22],
aphrodisiac [23], antitussive [24], cardioprotective and
hypotensive [25-27] activities. Their various effects on
central nervous system including improvement of spatial
cognitive abilities [28,29], anti-anxiety action [30], redu-
cing morphine withdrawal, morphine-induced condi-
tioned place preference, and dependence [31,32], and
anticonvulsant activities [33] were also investigated. The
antidepressant effects of different extracts of stigmas,
petals, and corms of C. sativus L. and their active constitu-
ents were evaluated in acute preclinical studies and shown
to be significantly more beneficial than placebo [34-37]. In
the present study, we first investigated the antidepressant
effects of crocin in rats using the FST; then, the protein
and transcript levels of CREB, BDNF, and VGF in rat
hippocampus were measured in order to understand the




Adult male Wistar Albino rats, weighing 250–300 g,
were provided by Animal House, School of Pharmacy,
Mashhad University of Medical Sciences, Iran. Four rats
were housed in standard plastic cages in the colony
room under 12-h light/dark cycle, 22 ± 2°C and 40-50%
humidity conditions. Animals had free access to food and
water before and during the study. This study was
approved by the ethical committee (No:88587) of Mash-
had University of Medical Sciences.
Chemicals
High Pure RNA Tissue Kit (#12033674001, Roche,
Germany) was used for RNA extraction and EXPRESS
One-Step SYBR® GreenER™ SuperMix Kit (#11780-200,
Invitrogen, USA) for qRT-PCR. Bio-Rad Protein Assay
Kit (#500-0002, Bio-Rad, USA) to determine protein con-
tents. Imipramine hydrochloride obtained from Marham
Daru, Iran. Tris–HCl, (ethylenediaminetetraacetic acid)
EDTA, Sodium fluoride (NaF), sodium orthovanadate
(Na3VO4), β-glycerol phosphate, sodium deoxycholate
(NaDC), complete protease inhibitor cocktail (P8340),
phenylmethylsulfonyl fluoride (PMSF), Sodium dodecyl
sulfate (SDS), 2-mercaptoethanol (2-ME), Bromophenol
blue (BPB), glycerol, and Tris Buffered Saline with Tween®
20 (TBST ), and Tween® 20 purchased from Sigma-
Aldrich, Germany.
Crocin extraction
Crocin was extracted and purified as previously descri-
bed by Hadizadeh and colleagues [38]. Ten g saffron
stigmas powders were suspended in 25 mL ethanol 80%
(0°C) and vortexed for 2 min. After that, the suspension
was centrifuged at 4000 rpm for 10 min and the super-
natant was separated. This step was repeated 6 times by
addition of 25 mL ethanol 80%. The resulting extract
was kept in a sealed thick walled glass container at −5°C
for 24 days in darkness. The formed crystals were sepa-
rated from the solution and washed with acetone to
remove remaining water. The obtained crystals were
then dissolved in 120 mL ethanol 80% and kept at −5°C
for 20 extra days. The purity of total crocin was more
than 97% and the amount of obtained crocin from the
initial stigmas powder was 10%. The purity of crocin
crystals was determined using UV-visible spectropho-
tometery and HPLC [38].
Treatments
Thirty rats were randomly divided into 5 different treat-
ment groups (n = 6). Different doses of crocin (12.5, 25,
and 50 mg/kg) [28,39] were administered intraperitone-
ally (IP) for 21 days. Neutral and positive control groups
received (IP) 1 mL/kg saline and 10 mg/kg imipramine,
respectively [40,41]. Crocin and imipramine were dis-
solved in saline right before injections. All treatments
were injected in a volume of 1 mL/kg. After 21 days of
treatment, rats were examined in the FST one hour after
the final injections. Then, all treated rats were killed by
decapitation. Hippocampi were separated immediately
and frozen in liquid nitrogen and stored at −80°C
until use.
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Forced swimming test (FST)
The FST was conducted between 10:00 and 14:00 hours.
The test involved two individual sections (2 days) using
a cylindrical tank made of glass, 80 cm tall, 30 cm in
diameter, and filled with water (23-25°C) to a depth of
40 cm in which rats could not touch the bottom of the
tank. On the 1st day (pretest), rats placed individually in
the tank for 15 min and then they were removed from
the water and placed in cages equipped with warmers.
Tanks were cleaned and filled with fresh water between
experiments. Twenty four hours after the pretest, rats
were retested for 6 min under the same condition. The
retest observations were recorded using a Panasonic
digital camcorder (Model NO. NV-DS65EN). During the
last 4 min of the retest, immobility (no additional activ-
ity other than those movements necessary to keep the
rat head off the water) times were scored by an observer
unaware of the treatment groups [42,43].
Tissue collection
Rats (n = 6) immediately were sacrificed by decapitation
after the FST under stress free conditions. Each decapi-
tation performed in a room isolated from other rodents.
The animal head was positioned completely in the open-
ing of the guillotine and guillotine lever was quickly
depressed. After that, Brain was removed, dissected on
ice in 3–4 min following decapitation. The brain was cut
in half using a midline incision and the midbrain was
gently removed. The hippocampus is delineated by a
large vessel running along its length. Hippocampi were
isolated; tissue at each end of them was cut, washed
by saline, rapidly frozen in liquid nitrogen and stored
at −80°C for subsequent processing.
Protein extraction
To prepare samples for western blotting, tissues were
homogenized in the homogenization buffer containing
Tris–HCl 50 mM ( pH: 7.4), 2 mM EDTA, 10 mM NaF,
1 mM Na3VO4, 10 mM β-glycerol phosphate, 0.2% w/v
NaDC, 1 mM PMSF, and complete protease inhibitor
cocktail using polytron homogenizer (POLYTRON® PT
10–35, Kinematica, Switzerland) in ice. After centrifuga-
tion at 10000 × g for 15 min at 4°C, Supernatants were
collected on ice and protein contents were determined
using Bio-Rad Protein Assay Kit and all concentrations
were adjusted to 10 mg/mL. Equal volumes of SDS sample
buffer containing 4% w/v SDS, 10% v/v 2-ME, 100 mM
Tris-base, 0.2% w/v BPB, and 20% v/v glycerol were added
to the samples and incubated in boiling water for 5 min.
Blue homogenates were stored at −80°C until use.
Western blot
Immuno blotting analysis performed on the prepared
samples to assess the levels of CREB, p-CREB, BDNF,
and VGF. Briefly, samples containing equivalent amounts
of 50 μg of total protein were loaded to SDS-PAGE gel
and then transferred to PVDF membrane by electrophor-
esis. Blots were blocked with 5% non-fat dry milk in TBST
for 3 h at room temperature. After blocking, blots were
probed with specific primary antibodies: rabbit monoclo-
nal anti-serum against CREB (#9197, Cell Signaling, USA),
mouse monoclonal anti-serum against p-CREB (Ser133)
(#9196, Cell Signaling, USA), rabbit polyclonal anti-
serum against BDNF (#ab46176, Abcam, USA) and VGF
(#ab74140, Abcam, USA), and mouse and rabbit mono-
clonal anti-serums against β-actin (# 3700 and # 4970, Cell
Signaling, USA) at 1:1000 dilutions for 2 h at room
temperature. Membranes were washed 3 times with 0.1%
Tween® 20 and TBST. Then, blots were incubated with
antimouse and rabbit horse radish peroxidase labeled IgG
(#7076 and #7074, Cell Signaling, USA) as secondary
antibodies at 1:3000 dilutions for 1 h at room temperature.
Finally, protein bands were visualized using an enhanced
chemiluminescence reagent (Pierce ECL western blotting
substrate) and Alliance Gel-doc (Alliance 4.7 Gel doc,
UVtec UK). UV Tec software (UK) was used to semi
quantify protein bands intensities. All blots were nor-
malized against intensities of corresponding β-actin
protein bands.
RNA extraction
Total RNAs were extracted from rat hippocampi using
High Pure RNA Tissue Kit according to the manu-
facturer’s instructions. The quantity and quality of the
isolated RNAs were assessed using NanoDrop 2000
UV–vis spectrophotometer (Thermo Scientific, USA).
Quantitative RT-PCR
QRT-PCR was performed to analyze transcript levels of
CREB, BDNF, and VGF using EXPRESS One-Step SYBR®
GreenER™ SuperMix Kit for one-step qRT-PCR accord-
ing to the manufacturer’s instructions and a StepOne™
Real-Time PCR System (ABI, USA). Data were analyzed
using the ΔΔCt method [44].
The following real-time PCR protocol was used for all
genes: activation of reverse transcriptase and cDNA syn-
thesis (5 min @ 50°C), PCR activation (2 min @ 95°C),
40 cycles of denaturation (15 s @ 95°C) and annealing/
extension (1 min @ 60°C). At the end of the PCR, a
melting curve analysis was performed by gradually in-
creasing the temperature from 60 to 95°C with a heating
rate of 0.3°C/s.
Primers for the selected genes were designed using
Beacon designer 7.8 (Biosoft, USA) and their specificity
was confirmed by BLAST (http://www.ncbi.nlm.nih.gov/
tools/primer-blast/). β-actin was used as endogenous
control gene. Primers were purchased from Metabion
international AG, Germany (Table 1).
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Statistical analysis
Data were analyzed using GraphPad InStat version 3.00
(GraphPad Software, San Diego, California, USA) with
One-way Analysis of Variance (ANOVA) followed by
Tukey post-hoc test and plotted in GraphPad Prism
version 3.00 (GraphPad Software, San Diego California
USA). All data presented as mean ± Standard error of
the mean (S.E.M). P values less than 0.05 were consid-
ered to be statistically significant.
Results
Forced swimming test
As shown in Figure 1, subacute administration of crocin
(12.5 and 50 mg/kg: **p < 0.01; 25 mg/kg: *p < 0.05) and
imipramine (10 mg/kg, **p < 0.01) significantly reduced
the immobility time as compared with neutral control
group that received saline. All doses of crocin could
reduce the immobility time, but not in a dose dependent
manner.
Western blot assay
Effects of the subacute treatment with crocin (12.5, 25,
and 50 mg/kg, IP) on the CREB, p-CREB, BDNF, and
VGF protein expression in the hippocampus are shown
in Figure 2. Statistical analysis indicated a significant and
dose-dependent effect of treatment with crocin on the
CREB expression as compared with control: 25 mg/kg
(37.80%, *p < 0.05) and 50 mg/kg (55.6%, ***p < 0.001).
Effect of imipramine on the CREB level was higher than
that of in crocin treated groups (Figure 2A). Crocin at a
dose of 12.5 mg/kg showed no appreciable effect on the
CREB expression as compared with saline group. Treat-
ment with high dose of crocin (50 mg/kg) significantly
increased the expression of p-CREB (43.52%, **p < 0.01)
as shown in Figure 2B. As shown in Figure 2C, there
were 41.63% (**p < 0.01) and 67.79% (***p < 0.001) in-
crease in the levels of BDNF after treatment with 25 and
50 mg/kg crocin as compared with control, respectively.
Treatment with 12.5 mg/kg crocin could not signifi-
cantly change the BDNF protein level. The effect of
50 mg/kg crocin on the level of BDNF was similar to
10 mg/kg imipramine (***p < 0.001 vs. saline). Crocin at
all doses, compared to saline, could significantly and
dose dependently increase the VGF levels in a dose-
dependent manner: 12.5 mg/kg (32.95%, p < 0.05),
25 mg/kg (54.35%, p < 0.001), and 50 mg/kg (80.54%,
p < 0.001). Crocin at doses of 25 and 50 mg/kg could
increase the VGF levels similar to that of imipramine
(***p < 0.001 vs. saline, Figure 2D).
Quantitative RT-PCR
Figure 3 illustrates the effects of the subacute treatment
with crocin (12.5, 25, and 50 mg/kg, IP) and imipramine
(10 mg/kg, IP) on the CREB, BDNF and VGF transcript
levels in rat hippocampi. The lowest dose of crocin
(12.5 mg/kg) could significantly increase the BDNF tran-
script levels in the hippocampus (*p < 0.05) as compared
with saline group. No significant changes were observed
in the transcript levels of CREB and VGF in different
experimental groups.
Discussion
In the present study we demonstrated that subacute
administration of crocin in all doses (12.5, 25, and
50 mg/kg) decreased the immobility time of rats in the
forced swimming test (FST), however this effect was not
in a dose-dependent manner. Subacute treatment with
10 mg/kg imipramine as positive control also decreased
the immobility time. In order to understand the mole-
cular mechanism of crocin-induced subacute antide-
pressant effects in the hippocampus, the protein and
transcript levels of anti-depressant related genes were
studied. Our data showed that crocin increased the
protein levels of CREB, p-CREB, BDNF, and VGF in the
Table 1 Primers used for qRT-PCR
Gene Amplicon
length (bp)
VGF Forward 5′-GATGACGACGACGAAGAC-3′ 100
Reverse 5′-CGATGATGCTGACCACAT-3′
β-actin Forward 5′GGGAAATCGTGCGTGACATT-3′ 76
Reverse 5′- GCGGCAGTGGCCATCTC-3′
CREB Forward 5′-CCAAACTAGCAGTGGGCAGT-3′ 140
Reverse 5′- GAATGGTAGTACCCGGCTGA-3′
BDNF Forward 5′-TCTACGAGACCAAGTGTAATCC-3′ 152
Reverse 5′- TATGAACCGCCAGCCAAT-3′
Figure 1 Effects of the subacute administration of crocin and
imipramine on immobility time of rats subjected to the forced
swimming test. The data are expressed as mean ± S.E.M; n = 6. All
groups were compared to neutral control group (saline) according
to ANOVA followed by Tukey post-hoc test: *p < 0.05, **p < 0.01.
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hippocampus. Treatment with 12.5 mg/kg crocin signifi-
cantly increased in BDNF transcript level.
In late 1970s, FST was accepted as a beneficial model
to predict the antidepressant effects of drugs on animal
[42]. The antidepressant effects of different saffron
extracts and crocin in acute administration in mice and
rats have already been reported in previous studies using
the FST. Furthermore, in the open field activity test, cro-
cin did not show a significant effect on total locomotion
[34-37]. The studies have been reported that acute and
chronic administration of imipramine (10 mg/kg) sig-
nificantly reduced the immobility time and confirmed
its antidepressant effects [40,41]. In our study, imipra-
mine (10 mg/kg) like previous reports decreased the
immobility time as compared with neutral control
group. The administration of crocin in different doses
also reduced the immobility time, similar to that of
imipramine. Therefore, our results suggest that crocin
has antidepressant effects in subacute treatment.
Hippocampus is a region in the brain that plays a
central role in processing of emotions and controlling of
behavior in response to fear and anxiety [45]. Preclinical
and Clinical studies have shown that the hippocampus is
affected by stress. Death and atrophy of hippocampal
neurons have been reported in rats exposed to stress
and high levels of glucocorticoids [46]. The reduction of
hippocampus size in patients with recurrent depression
and posttraumatic stress disorder has been observed
Figure 2 Effects of the subacute administration of crocin and imipramine on protein levels of A: CREB, B: p-CREB, C: BDNF, and D: VGF
in the hippocampi. The graphics show the mean ± S.E.M. of separate experiments: n = 6. All groups were compared to neutral control group
(saline) according to ANOVA followed by Tukey post-hoc test: *p < 0.05, **p < 0.01, ***p < 0.001. β-actin: endogenous control.
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[47-49]. It is well established that structural and func-
tional modifications of hippocampus are associated with
antidepressant treatments. These changes include alter-
ations in synaptic plasticity, neurogenesis, and synapto-
genesis and most likely require the transcription and
protein expression of new molecules such as CREB,
BDNF and VGF [7].
Chronic treatment with antidepressants enhances,
activates and induces the phosphorylation of CREB that
produces antidepressant behavioral response in rodents
and human [7,11,50,51]. Various antidepressants have
shown different effects on CREB protein and mRNA
levels. For example, 21 days administration of several
different types of antidepressant drugs including fluo-
xetine (a serotonin (5-HT) selective reuptake inhibitor),
desipramine (a selective norepinephrine (NE) reuptake
inhibitor), imipramine (a nonselective 5-HT and NE
reuptake inhibitor, 15 mg/kg), and tranylcypromine (a
monoamine oxidase inhibitor) significantly increased
levels of CREB mRNA in rat hippocampus and only
fluoxetine significantly increased CREB protein levels
[11,51]. Conversely, similar doses and time course of ad-
ministration showed that neither desmethylimipramine
nor fluoxetine could increase CREB protein levels;
however, both could increase CREB phosphorylation,
but only in the frontal cortex and not in the hippocam-
pus [11]. In addition, it was shown that imipramine at
dose of 20 mg/kg could only increase CREB protein
levels in prefrontal cortex but not in hippocampus [52].
The administration of fluoxetine and reboxetine (a NE
reuptake inhibitor) for 14 days at a dose of 10 mg/kg
resulted in increased levels of CREB mRNA in the
hippocampus, but desipramine at the same dose did not
have significant effect on CREB mRNA level [50]. In
transgenic mice model of depression imipramine
(10 mg/kg) increased CREB mRNA levels only in the
cortex, whereas fluoxetine (10 mg/kg) could increase the
levels of CREB mRNA in the cortex and the hippocam-
pus [53]. The results of the present study showed that
crocin administration could increase the CREB protein
levels in the hippocampus dose dependently. P-CREB
significantly increased only with 50 mg/kg of crocin.
Desmethylimipramine and fluoxetine has been reported
to increase CREB phosphorylation in other region of the
brains like cortex [11]. In our study, no significant
changes in CREB mRNA levels were observed in hippo-
campus. Therefore, crocin-induced changes in CREB
and p-CREB protein and CREB mRNA levels may be
Figure 3 Effects of the subacute administration of crocin and imipramine on transcript levels of A: CREB, B: BDNF, and C: VGF. Data are
expressed as mean ± S.E.M; n = 4. All groups were compared to neutral control group (saline) according to ANOVA followed by Tukey post-hoc
test: *p < 0.05.
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involved in other brain regions such as cortex similar to
previous reports [11,53]. However more supportive data
are necessary to confirm this hypothesis.
BDNF structurally belongs to the neurotrophin family
that plays an important role in regulation of neuronal dif-
ferentiation including neurotransmitter content and neur-
onal survival [54]. Recent studies have shown that after
treatment with antidepressants, levels of BDNF signifi-
cantly increased in plasma [55,56]. It was evidenced that
use of imipramine as a nonselective 5-HT and NE re-
uptake inhibitor at doses of 10 and 20 mg/kg was effective
to increase BDNF protein levels in both prefrontal cortex
and hippocampus [52]. It has been shown that longer
treatment with citalopram (a serotonergic agent) could
significantly increase the level of BDNF transcript [57]. In
addition, both acute and chronic use of norepinephrine
re-uptake inhibitors (desipramine and maprotiline) had no
effect on BDNF mRNA levels, while serotonergic antide-
pressants (fluoxetine and paroxetine) altered BDNF gene
expression, but not in acute administration [58]. In the
current study, subacute treatment with crocin in a dose-
dependent manner increased the BDNF protein levels
compared to the neutral control treatment group. Crocin
could significantly increase the BDNF transcript level as
compared to saline group. Due to the result of present
and past studies, the effect of crocin on BDNF expression
levels is similar to serotonergic drugs.
VGF is a neuropeptide that has been shown to be in-
volved in maintaining energy balance, mediating hippo-
campal synaptic plasticity, and antidepressant responses
[7,59]. In several animal models of depression local
application of VGF into the midbrain or hippocampus
produced antidepressant responses [60]. Due to the
different studies, VGF gene is an important target for
BDNF and serotonin. This agent besides exercise may
activate intracellular pathways that may lead to the VGF
expression [59]. Antidepressants do not show the same
effects on VGF gene expression. Although Hunsberger
and colleagues reported that VGF expression was not
affected by different classes of antidepressants [61], there
are some reports that show fluoxetine and paroxetine,
but not imipramine and desipramine could increase the
VGF expression [60]. Our results showed that transcript
levels of VGF were not increased following administra-
tion of different doses of crocin, however, VGF protein
expression significantly and dose-dependently elevated
after treatment with crocin.
Conclusions
In conclusion, our study showed that subacute adminis-
tration of crocin has antidepressant effects in rats.
Crocin administration significantly increased the CREB,
p-CREB, BDNF, and VGF protein expressions in rat
hippocampus.
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